{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T17:41:02Z","timestamp":1773769262714,"version":"3.50.1"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Chronic hepatitis B virus (HBV) infection burden in children remains a pressing public health concern. Whether antiviral therapy should be administered to children with HBV in the immune-tolerant phase remains controversial. We performed a meta-analysis to evaluate antiviral therapy efficacy and safety in children with immune-tolerant hepatitis B (ITHB).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A search was conducted in multiple databases (PubMed, Embase, Cochrane, Web of Science, CBM, CNKI and Wanfang Data) to identify clinical trials examining antiviral therapy efficacy and safety in children (1\u201318 years) with ITHB viral infection from inception to February 2023. Outcomes were calculated separately for controlled and single-arm studies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Nine trials (442 patients), including 2 randomized controlled trials (RCTs), 3 non-RCTs and 4 single-arm studies, were included in this meta-analysis. In the RCTs, antiviral therapy group exhibited greater rates of HBsAg loss [risk ratio (RR) = 6.11, 95% confidence interval (CI): 1.67\u201322.31, P<jats:sub>Z-test<\/jats:sub> = 0.006], HBsAg serologic response (RR = 5.29, 95% CI: 1.47\u201319.07, P<jats:sub>Z-test<\/jats:sub> = 0.011) and HBeAg loss (RR = 3.00, 95% CI: 1.35\u20136.66, P<jats:sub>Z-test<\/jats:sub> = 0.007) compared with the control group at the end of follow-up. In single-arm studies, the pooled incidences of HBsAg loss, HBeAg loss and HBsAg seroconversion were 24% (95% CI: \u22120.1% to 48%), 24% (95% CI: \u22120.1% to 48%) and 24% (95% CI: \u22125% to 52%), respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Current evidence suggests the effectiveness of antiviral therapy in children with HBV infection in the immune-tolerant stage, with few serious adverse events. Due to the limited quality and number of included studies, more high-quality studies are required to validate our findings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004057","type":"journal-article","created":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T20:03:43Z","timestamp":1690833823000},"page":"942-948","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and Safety of Antiviral Therapy for Immune-tolerant Hepatitis B Viral Infection in Children: A Systematic Review and Meta-analysis"],"prefix":"10.1097","volume":"42","author":[{"given":"Fengli","family":"Zheng","sequence":"first","affiliation":[{"name":"Department of Pediatrics, The People\u2019s Hospital of Guigang, Guigang, Guangxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijun","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The People\u2019s Hospital of Guigang, Guigang, Guangxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhou","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The People\u2019s Hospital of Guigang, Guigang, Guangxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyao","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The People\u2019s Hospital of Guigang, Guigang, Guangxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,7,31]]},"reference":[{"key":"R1-20250614","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-015-0199-y","article-title":"Natural history of chronic hepatitis B virus infection from infancy to adult life -the mechanism of inflammation triggering and long-term impacts.","volume":"22","author":"Wu","year":"2015","journal-title":"J Biomed Sci"},{"key":"R3-20250614","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B.","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0140-6736(09)60207-5","article-title":"Hepatitis B virus infection.","volume":"373","author":"Liaw","year":"2009","journal-title":"Lancet"},{"key":"R5-20250614","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection.","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jhep.2013.05.016","article-title":"Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition.","volume":"59","author":"Sokal","year":"2013","journal-title":"J Hepatol"},{"key":"R7-20250614","first-page":"130","article-title":"Clinical manifestations and pathological changes of hepatitis B and C in children (Chinese).","volume":"41","author":"Zhang","year":"2006","journal-title":"Infect Dis Infor"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1053\/j.gastro.2012.06.009","article-title":"Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B.","volume":"143","author":"Kennedy","year":"2012","journal-title":"Gastroenterology"},{"key":"R9-20250614","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1053\/j.gastro.2016.07.012","article-title":"HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant.","volume":"151","author":"Mason","year":"2016","journal-title":"Gastroenterology"},{"key":"R10-20250614","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1136\/gutjnl-2017-314904","article-title":"High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.","volume":"67","author":"Kim","year":"2018","journal-title":"Gut"},{"key":"R12-20250614","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/ptj\/89.9.873","article-title":"Reprint--preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"89","author":"Moher","year":"2009","journal-title":"Phys Ther"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument.","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1371\/journal.pone.0000841","article-title":"Heterogeneity in meta-analyses of genome-wide association investigations.","volume":"2","author":"Ioannidis","year":"2007","journal-title":"PLoS One"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/sim.4780140406","article-title":"A random-effects regression model for meta-analysis.","volume":"14","author":"Berkey","year":"1995","journal-title":"Stat Med"},{"key":"R19-20250614","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cct.2006.04.004","article-title":"Random-effects model for meta-analysis of clinical trials: an update.","volume":"28","author":"Dersimonian","year":"2007","journal-title":"Contemp Clin Trials"},{"key":"R20-20250614","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease.","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"R21-20250614","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jhep.2018.01.037","article-title":"Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: a pilot open-label randomized study.","volume":"68","author":"Zhu","year":"2018","journal-title":"J Hepatol"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/MPG.0000000000003118","article-title":"Peginterferon Alfa-2a (40KD) plus lamivudine or entecavir in children with immune-tolerant chronic hepatitis B.","volume":"73","author":"Mieli-Vergani","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/jvh.12007","article-title":"Cure for immune-tolerant hepatitis B in children: is it an achievable target with sequential combo therapy with lamivudine and interferon?","volume":"20","author":"Poddar","year":"2013","journal-title":"J Viral Hepat"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1179\/joc.2005.17.2.198","article-title":"Lamivudine monotherapy in children with immune-tolerant chronic hepatitis B virus.","volume":"17","author":"Artan","year":"2005","journal-title":"J Chemother"},{"key":"R26-20250614","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s12664-018-0878-1","article-title":"Pegylated interferon-based sequential therapy for treatment of HBeAg reactive pediatric chronic hepatitis B-First study in children.","volume":"37","author":"Lal","year":"2018","journal-title":"Indian J Gastroenterol"},{"key":"R27-20250614","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jpeds.2005.09.020","article-title":"Combined lamivudine\/interferon-alpha treatment in \u201cimmunotolerant\u201d children perinatally infected with hepatitis B: a pilot study.","volume":"148","author":"D\u2019antiga","year":"2006","journal-title":"J Pediatr"},{"key":"R28-20250614","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1002\/hep.30312","article-title":"Combination of Entecavir\/Peginterferon Alfa-2a in children with hepatitis B e antigen-positive immune tolerant chronic hepatitis B virus infection.","volume":"69","author":"Rosenthal","year":"2019","journal-title":"Hepatology"},{"key":"R29-20250614","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/jvh.13154","article-title":"Long-term efficacy and safety of peginterferon in the treatment of children with HBeAg-positive chronic hepatitis B.","volume":"26","author":"Liu","year":"2019","journal-title":"J Viral Hepat"},{"key":"R30-20250614","first-page":"1558","article-title":"Clinical follow-up of children with immune-tolerant chronic hepatitis B receiving antiviral therapy (Chinese).","volume":"37","author":"Zhao","year":"2021","journal-title":"J Clin Hepatol"},{"key":"R31-20250614","first-page":"181","article-title":"GuoRealizing the meta-analysis of single rate in R software(Chinese).","volume":"13","author":"Luo","year":"2013","journal-title":"J Evid Based Med"},{"key":"R32-20250614","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection.","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"R33-20250614","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jhep.2014.11.031","article-title":"Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance.","volume":"62","author":"Kim","year":"2015","journal-title":"J Hepatol"},{"key":"R34-20250614","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S2468-1253(18)30308-X","article-title":"Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses.","volume":"4","author":"Zhou","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R35-20250614","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1080\/14787210.2021.1845652","article-title":"Spontaneous loss of chronic HBV infection markers in treatment-naive children: a systematic review and pooled meta-analyses.","volume":"19","author":"Yang","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R36-20250614","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/hep.1840100502","article-title":"Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? a statistical analysis of predictive factors.","volume":"10","author":"Brook","year":"1989","journal-title":"Hepatology"},{"key":"R37-20250614","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.cld.2016.06.002","article-title":"Interferon treatment for hepatitis B.","volume":"20","author":"Konerman","year":"2016","journal-title":"Clin Liver Dis"},{"key":"R38-20250614","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/hep.32400","article-title":"Changes in serum hepatitis B surface and e antigen, interferon-inducible protein 10, and aminotransferase levels during combination therapy of immune-tolerant chronic hepatitis B.","volume":"76","author":"Perrillo","year":"2022","journal-title":"Hepatology"},{"key":"R39-20250614","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s10620-009-0819-z","article-title":"Association of interleukin-18 gene polymorphisms with hepatitis B virus clearance.","volume":"55","author":"Cheong","year":"2010","journal-title":"Dig Dis Sci"},{"key":"R40-20250614","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1097\/INF.0000000000002876","article-title":"Efficacy and safety of pegylated interferon for the treatment of chronic hepatitis B in children and adolescents: a systematic review and meta-analysis.","volume":"39","author":"He","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"R41-20250614","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jpeds.2004.05.046","article-title":"Interferon treatment for chronic hepatitis B: enhanced response in children 5 years old or younger.","volume":"145","author":"Kobak","year":"2004","journal-title":"J Pediatr"},{"key":"R42-20250614","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0168-8278(05)80624-5","article-title":"The value of quantitative measurement of HBeAg and HBsAg before interferon-alpha treatment of chronic hepatitis B in children.","volume":"21","author":"Burczynska","year":"1994","journal-title":"J Hepatol"},{"key":"R43-20250614","first-page":"587","article-title":"A retrospective study on the liver pathological characteristics and the effect of antiviral treatment for 1 to 7 years old children with hepatitis B e antigen-negative chronic hepatitis B.","volume":"54","author":"Zhu","year":"2016","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"R44-20250614","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1053\/j.gastro.2014.01.044","article-title":"Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.","volume":"146","author":"Chan","year":"2014","journal-title":"Gastroenterology"},{"key":"R45-20250614","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/MEG.0000000000001345","article-title":"Tenofovir and telbivudine combination therapy rapidly decreases viral loads in immune-tolerant chronic hepatitis B patients awaiting assisted reproduction: an open-label, randomized, controlled study.","volume":"31","author":"Wu","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R46-20250614","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: towards a cure.","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat Rev Drug Discovery"},{"key":"R47-20250614","doi-asserted-by":"crossref","first-page":"104492","DOI":"10.1016\/j.meegid.2020.104492","article-title":"Extended duration therapy regimens based on Pegylated interferon for chronic hepatitis B patients focusing on hepatitis B surface antigen loss: a systematic review and meta-analysis.","volume":"85","author":"Ma","year":"2020","journal-title":"Infect Genet Evol"},{"key":"R48-20250614","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s12072-022-10415-7","article-title":"The effectiveness of combination therapy with interferon and nucleoside analogs in pediatric patients with chronic hepatitis B: a systematic review and meta-analysis.","volume":"17","author":"Li","year":"2023","journal-title":"Hepatol Int"},{"key":"R49-20250614","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1086\/368083","article-title":"Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.","volume":"36","author":"Lai","year":"2003","journal-title":"Clin Infect Dis"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:04:05Z","timestamp":1749945845000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,31]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004057","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,31]]}}}